» Articles » PMID: 15494480

Cutting Edge: Engagement of CD160 by Its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset

Overview
Journal J Immunol
Date 2004 Oct 21
PMID 15494480
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

CD160 is an Ig-like activating NK cell receptor expressed on the majority of circulating NK cells. This population corresponds to the nonproliferating, highly cytolytic, CD56dimCD16+ subset. CD160 engagement by HLA-C molecules mediates cytotoxic function. In this study, we report that upon specific activation by the physiological ligand HLA-C, or Ab cross-linking, CD160+ peripheral blood NK cells produce IFN-gamma, TNF-alpha, and IL-6. This unique CD160-mediated cytokine production differs from the one observed after CD16 engagement whose expression is also restricted to the CD56dim cytotoxic NK cell subset. As already reported for the CD160-mediated cytotoxic effector function, CD160-mediated cytokine production by peripheral blood-NK cells is negatively controlled by the killer Ig-like receptor CD158b. Thus, the CD160 receptor represents a unique triggering surface molecule expressed by cytotoxic NK cells that participates in the inflammatory response and determines the type of subsequent specific immunity.

Citing Articles

Virus-specific Th17 Cells Are Induced by Human Cytomegalovirus after Renal Transplantation.

Dhital R, Flint K, Kaptsan I, Hegde S, Daloul R, Shimamura M J Immunol. 2024; 213(11):1703-1712.

PMID: 39423238 PMC: 11573647. DOI: 10.4049/jimmunol.2300742.


Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.

Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y Breast Cancer Res. 2024; 26(1):28.

PMID: 38360636 PMC: 10870674. DOI: 10.1186/s13058-024-01785-x.


γδ T cells mediate robust anti-HIV functions during antiretroviral therapy regardless of immune checkpoint expression.

Field K, Wragg K, Kent S, Lee W, Juno J Clin Transl Immunology. 2024; 13(2):e1486.

PMID: 38299190 PMC: 10825377. DOI: 10.1002/cti2.1486.


Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.

Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Diaz R, Martinez-Perez A, Aguilar-Garcia C, Rodrigo J Mol Cancer. 2023; 22(1):142.

PMID: 37649037 PMC: 10466776. DOI: 10.1186/s12943-023-01845-4.


Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.

Zhang M, Lam K, Xu S Front Immunol. 2023; 14:1207276.

PMID: 37638058 PMC: 10450036. DOI: 10.3389/fimmu.2023.1207276.